Sandbox:Madhu

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahmoud Sakr, M.D. [2]

Overview

Coagulation necrosis, characterized by Hypereosinophilia and nuclear pyknosis followed by karyorrhexis, karyolysis, total loss of nuclei and loss of cytoplasmic cross-striations is generally first visible in the period from 4,12 hours following infarction. necrotic myocytes may retain their striations for a long time Neutrophilic infiltration (Acute inflammation) edema and hemorrhage are also first visible at 4-12 hours but generally closer to 12 hours. the interstitium at the margin of the Infarcted area is initially infiltrated with Neutrophils, then with Lymphocytes and Macrophages, who phagocytose or eat the myocyte debris; The necrotic area is surrounded and progressively invaded by granulation tissue: which will replace the infarct with a fibrous or collagenous scar (which are typical steps in wound healing). the interstitial space or the space between cells outside of blood vessels may be infiltrated with red blood cells. Infiltration by macrophages, lymphocytes, eosinophils, fibroblasts and capillaries begins around the periphery at 3-10 days. contraction band necrosis, characterized by hypereosinophilic transverse bands of precipitated Myofibrils in dead myocytes is usually seen at the edge of an Infarct or with reperfusion for example with Thrombolytic therapy.

Classification of DES

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Classification

• There is no established system for the classification of [disease name].

OR

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [Group1]
  • [Group2]
  • [Group3]
  • [Group4]

OR

• [Disease name] may be classified into [large number > 6] subtypes based on:
  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]
• [Disease name] may be classified into several subtypes based on:
  • [Classification method 1]
  • [Classification method 2]
  • [Classification method 3]

OR

• Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

• If the staging system involves specific and characteristic findings and features:
• According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

• The staging of [malignancy name] is based on the [staging system].

OR

• There is no established system for the staging of [malignancy name].